Print this page    •   Back to Web version of article

U.S. News
Gilead Sciences First-Quarter Profits Driven by Increase in Sales of Antiretroviral Viread

April 26, 2004

Foster City, Calif.-based Gilead Sciences on Thursday announced first-quarter 2004 net profits of $114.4 million, up from a net loss of $438.1 million during the same quarter last year, an increase largely driven by sales of its antiretroviral drug Viread, Reuters reports (Berkrot/Pierson, Reuters, 4/22). Gilead -- which manufactures Viread, the fifth best-selling antiretroviral drug in the United States -- in July 2003 launched a second antiretroviral drug, Emtriva, and is developing a once-daily combination pill to compete with industry leader GlaxoSmithKline's top-selling Combivir (Kaiser Daily HIV/AIDS Report, 10/30/03). Sales of Viread increased 80% to $193.1 million during the first quarter of 2004, and the company raised its yearly sales forecast for the drug to between $725 million and $775 million. In addition, sales of Emtriva reached $12 million in the first quarter. The company also said it plans to start clinical trials of a new protease inhibitor, according to Reuters (Reuters, 4/22).

Back to other news for April 26, 2004


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.




This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art11217.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.